Publications by authors named "B J Cuffel"
Article Synopsis
- * The CSS was developed using five key symptoms (pain, fatigue, shortness of breath, muscle weakness, coughing) identified from the MD Anderson Symptom Inventory for MPM and showed a strong correlation with other established symptom measurement scales.
- * This new score is user-friendly, allowing for frequent electronic administration, making it a valuable tool for assessing symptom changes during clinical trials and improving patient management in practice.
Article Synopsis
- The study examines the cost-effectiveness of next-generation sequencing (NGS) compared to sequential single-gene testing (SGT) for identifying patients with actionable genomic alterations in various cancers.
- A cost calculator was developed using sensitivity and specificity data to estimate the cost per correctly identified patient (CCIP) for both testing methods.
- Results show that NGS was generally more cost-effective than SGT for most cancers, suggesting that NGS may become the preferred approach in precision oncology as prices decrease and targeted therapies expand.
Objective: The results from basket trials utilized to gain regulatory approval of tumor-agnostic therapies can be difficult to interpret without the context of a comparator arm. We describe the role and efficacy of histology-based treatments to provide a historical comparison with larotrectinib.
Methods: A systematic literature review (SLR) was conducted on the clinical outcomes of current histology-based standard of care treatments used in non-small cell lung cancer, colorectal cancer, thyroid cancer, gliomas, soft tissue sarcoma, salivary gland cancer, and infantile fibrosarcoma (7 of the 21 tumor histologies in the larotrectinib trials).
Background: Symptom assessment requires psychometrically validated questionnaires that are easy to use, relevant to the disease, and quick to administer. The MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) was adapted from the general (core) MDASI to assess the severity of cancer-related and treatment-related symptoms specific to patients with this condition. The MDASI-MPM includes the 13 core MDASI symptoms, which are experienced by most cancer patients, and 6 MPM-specific items developed via qualitative interviewing, a method favored by the US Food and Drug Administration for instrument item generation and development.
View Article and Find Full Text PDFPurpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer of the lung pleura. The MD Anderson Symptom Inventory (MDASI) is a patient-reported outcome (PRO) measure of symptom burden, the combined impact of disease-related and treatment-related symptoms on functioning. Validated PRO measures may require modification for use in specific study populations.
View Article and Find Full Text PDF